PRNPIP Inhibitors
PRNPIP inhibitors encompass a selective array of chemical compounds that intervene in various signaling pathways, resulting in the attenuation of PRNPIP's functional activity. Compounds like PD 98059 and U0126 target the MAPK/ERK pathway, a signaling cascade that, when inhibited, prevents the phosphorylation events necessary for PRNPIP activity, thereby reducing its role in cell proliferation and differentiation. Similarly, LY 294002 and Wortmannin, as PI3K inhibitors, impede the PI3K/AKT pathway, which is fundamental for a spectrum of cellular functions including those in which PRNPIP is implicated, thus indirectly leading to decreased PRNPIP activity. The inhibition of mTOR by Rapamycin disrupts downstream signaling that could involve PRNPIP in protein synthesis and cell growth, further contributing to the dampening of PRNPIP's influence on these processes. Additionally, the modulation of stress response and cytokine production pathways by SB 203580, an inhibitor of p38 MAP kinase, and SP600125, a JNK inhibitor, provides a further avenue for diminishing PRNPIP activity by altering cellular responses where PRNPIP is a potential player.
Furthermore, kinase inhibitors such as WZ8040, Triciribine, and Gö 6983 disrupt key phosphorylation processes that could impact PRNPIP's functionality. By inhibiting NUAK kinases, AKT, and PKC, respectively, these compounds prevent necessary post-translational modifications or signaling events essential for PRNPIP's role in cell metabolism and proliferation. BIX 02189's inhibition of MEK5 leads to a decrease in ERK5 pathway activity, reducing signaling that is potentially crucial for PRNPIP's involvement in gene expression control. Lastly, SL-327, targeting MEK1/2 and ERK1/2, broadly suppresses the MAPK/ERK pathway, further ensuring a comprehensive downregulation of PRNPIP's activity within various cellular processes. These inhibitors, through their targeted actions, collectively contribute to a strategic reduction in PRNPIP's activity without affecting its expression levels, delineating a multifaceted approach to controlling this protein's functional influence.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 is a potent MEK inhibitor that obstructs the MAPK/ERK pathway. By inhibiting this pathway, the downstream signaling that might include phosphorylation events necessary for PRNPIP activity is diminished. This results in an indirect inhibition of PRNPIP's functional role in cellular processes governed by this pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor that disrupts the mTORC1 signaling pathway. PRNPIP, which may be involved in downstream processes regulated by mTORC1, will have its functional activity decreased as a result of mTOR signaling interference, leading to diminished protein synthesis and cell growth that are typically promoted by PRNPIP. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002 is a PI3K inhibitor that leads to the blockade of the PI3K/AKT pathway. This pathway's inhibition can indirectly lead to decreased PRNPIP activity, as PI3K/AKT is instrumental in numerous cellular functions, including those that may involve PRNPIP's role in signaling or metabolic processes. | ||||||
WZ8040 | 1214265-57-2 | sc-364656 sc-364656A | 5 mg 10 mg | $255.00 $480.00 | ||
WZ8040 is a selective NUAK kinase inhibitor that can reduce the activity of kinases that may phosphorylate PRNPIP, thus reducing PRNPIP's activity by preventing its necessary post-translational modifications which are crucial for its function in cellular signaling related to cell proliferation and metabolism. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB 203580 is an inhibitor of p38 MAP kinase. Inhibition of p38 MAPK can lead to diminished PRNPIP activity by affecting the signaling pathways that regulate stress responses and cytokine production, which PRNPIP could be implicated in. The stress response modulation may indirectly decrease PRNPIP activity by altering cellular responses. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
Triciribine is an AKT inhibitor that, by inhibiting AKT, reduces the phosphorylation of downstream targets that may involve PRNPIP. This results in diminished PRNPIP activity related to growth factor signaling and apoptosis regulation, as AKT is a key player in these processes. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor that, by blocking JNK, can reduce the activity of transcription factors that might regulate PRNPIP expression or function. This could lead to decreased PRNPIP activity as JNK signaling is important for apoptosis and other stress responses that PRNPIP might be involved with. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $105.00 $299.00 $474.00 | 15 | |
Gö 6983 is a potent PKC inhibitor that disrupts PKC-mediated signaling pathways. PRNPIP's activity could be diminished as a result since PKC is involved in numerous cell signaling processes, including those regulating cell cycle and proliferation that may require PRNPIP's function. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent PI3K inhibitor that decreases AKT activation, thereby affecting processes that PRNPIP might be involved in, such as cell survival and metabolism. With the PI3K/AKT pathway inhibited, PRNPIP's functional activity in these processes is diminished. | ||||||
BIX 02189 | 1094614-85-3 | sc-364436 sc-364436A | 5 mg 10 mg | $224.00 $386.00 | 5 | |
BIX 02189 is a MEK5 inhibitor that blocks the ERK5 pathway. With this pathway inhibited, the signaling that could involve PRNPIP in cellular functions such as gene expression and cell proliferation is diminished, leading to a decrease in PRNPIP's functional activity. | ||||||